DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

Journal of Clinical Oncology

Volumn 28, Issue 4, 2010, Pages 605-613

  Shen, Lanlan ^a   Kantarjian, Hagop ^a   Guo, Yi ^a   Lin, E ^a   Shan, Jianqin ^a   Huang, Xuelin ^a   Berry, Donald ^a   Ahmed, Saira ^a   Zhu, Wei ^a   Pierce, Sherry ^a   Kondo, Yutaka ^a   Oki, Yasuhiro ^a   Jelinek, Jaroslav ^a   Saba, Hussain ^a   Estey, Eli ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; FEMALE; FOLLOW UP; GENE FREQUENCY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PYROSEQUENCING; TREATMENT RESPONSE; VALIDATION STUDY; CANCER STAGING; COHORT ANALYSIS; DISEASE FREE SURVIVAL; GENETICS; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; COHORT STUDIES; CPG ISLANDS; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77449149371     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.4781     Document Type: Article

References (31)

1. Gilliland DG: Hematologic malignancies. Curr Opin Hematol 8:189-191, 2001
2. Komrokji RS, Bennett JM: Evolving classifications of the myelodysplastic syndromes. Curr Opin Hematol 14:98-105, 2007
3. Valent P, Horny HP, Bennett JM, et al: Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31:727-736, 2007
4. Haase D, Germing U, Schanz J, et al: New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: Evidence from a core dataset of 2124 patients. Blood 110:4385-4395, 2007
5. Kantarjian H, Issa JP, Rosenfeld CS, et al: Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study. Cancer 106:1794-1803, 2006
6. Kantarjian H, Oki Y, Garcia-Manero G, et al: Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57, 2007
7. Issa JP: DNA methylation as a therapeutic target in cancer. Clin Cancer Res 13:1634-1637, 2007
8. Jones PA, Baylin SB: The fundamental role of epigenetic events in cancer. Nat Rev Genet 3:415-428, 2002
9. Christiansen DH, Andersen MK, Pedersen-Bjergaard J: Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapyrelated myelodysplasia and acute myeloid leukemia. Leukemia 17:1813-1819, 2003
10. Lin J, Yao DM, Qian J, et al: Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res 32:1541-1545, 2008
11. Quesnel B, Guillerm G, Vereecque R, et al: Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990, 1998 (Pubitemid 28227550)
12. Tien HF, Tang JH, Tsay W, et al: Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 112:148-154, 2001 (Pubitemid 32151162)
13. Wu SJ, Yao M, Chou WC, et al: Clinical implications of SOCS1 methylation in myelodys-plastic syndrome. Br J Haematol 135:317-323, 2006 (Pubitemid 44484838)
14. Aggerholm A, Holm MS, Guldberg P, et al: Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76:23-32, 2006
15. Grövdal M, Khan R, Aggerholm A, et al: Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following myelodysplastic syndrome. Clin Cancer Res 13:7107-7112, 2007
16. Colella S, Shen L, Baggerly KA, et al: Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques 35:146-150, 2003 (Pubitemid 36828724)
17. Cheadle C, Vawter MP, Freed WJ, et al: Analysis of microarray data using Z score transformation. J Mol Diagn 5:73-81, 2003 (Pubitemid 36553428)
18. Toyota M, Kopecky KJ, Toyota MO, et al: Methylation profiling in acute myeloid leukemia. Blood 97:2823-2829, 2001
19. Shen L, Toyota M, Kondo Y, et al: Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 101:4131-4136, 2003 (Pubitemid 36857895)
20. Boumber YA, Kondo Y, Chen X, et al: RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 67:1997-2005, 2007
21. Jelinek J, Mannari R, Issa JP: Identification of 41 novel promoter-associated CpG islands methylated in leukemias. Blood 2004:319a, 2004 (abstr)
22. Toyota M, Issa JP: Methylated CpG island amplification for methylation analysis and cloning differentially methylated sequences. Methods Mol Biol 200:101-110, 2002
23. Toyota M, Ahuja N, Ohe-Toyota M, et al: CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 96:8681-8686, 1999 (Pubitemid 29354851)
24. Huang TH, Perry MR, Laux DE: Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8:459-470, 1999 (Pubitemid 29097334)
25. Liang G, Salem CE, Yu MC, et al: DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53:260-268, 1998 (Pubitemid 28527627)
26. Toyota M, Ahuja N, Suzuki H, et al: Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59: 5438-5442, 1999
27. Ueki T, Toyota M, Sohn T, et al: Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 60:1835-1839, 2000
28. Boyes J, Bird A: Repression of genes by DNA methylation depends on CpG density and promoter strength: Evidence for involvement of a methyl-CpG binding protein. EMBO J 11:327-333, 1992
29. Turker MS: The establishment and maintenance of DNA methylation patterns in mouse somatic cells. Semin Cancer Biol 9:329-337, 1999 (Pubitemid 29532859)
30. Issa JP, Baylin SB, Belinsky SA: Methylation of the estrogen receptor CpG island in lung tumors is related to the specific type of carcinogen exposure. Cancer Res 56:3655-3658, 1996
31. Shen L, Ahuja N, Shen Y, et al: DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 94:755-761, 2002 (Pubitemid 34567960)